AGRX Agile Therapeutics, Inc.

2.52
+0  (0%)
Previous Close 2.52
Open 2.53
Price To book 1.55
Market Cap 72.47M
Shares 28,757,000
Volume 564,888
Short Ratio 3.69
Av. Daily Volume 483,368

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515835
  2. 8-K - Current report 17502375
  3. 8-K - Current report 162026876
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978397
  5. 8-K - Current report 161978323

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data but intends to reflile NDA 1H 2017.
Twirla
Contraceptive patch

Latest News

  1. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline: March 7, 2017
  2. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  3. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  4. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Agile Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
  5. IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Agile Therapeutics, Inc. (AGRX) To Contact Brower Piven Before The Lead Plaintiff Deadl
  7. Robbins Arroyo LLP: Agile Therapeutics, Inc. (AGRX) Misled Shareholders According to a Recently Filed Class Action
  8. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  9. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline: March 7, 2017
  10. EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  11. Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Agile Therapeutics, Inc. (AGRX)
  12. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Agile Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 7, 2017 – AGRX
  13. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  14. Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Agile Therapeutics, Inc.
  15. IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces a Class Action Lawsuit Against Agile Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm
  16. The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Agile Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm
  17. AGILE (AGRX) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Agile Therapeutics, Inc.; Encourages all Investors to Contact the Firm for Information
  18. Harwood Feffer LLP Announces Investigation of Agile Therapeutics, Inc.
  19. AGILE NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Agile Therapeutics, Inc. To Contact The Firm
  20. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Agile Therapeutics, Inc. – AGRX

SEC Filings

  1. 8-K - Current report 17515835
  2. 8-K - Current report 17502375
  3. 8-K - Current report 162026876
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978397
  5. 8-K - Current report 161978323
  6. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161955716
  7. 8-K - Current report 161925418
  8. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161915811
  9. 8-K - Current report 161855134
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161814304